Operator: Good morning. Welcome to the Lantheus Fourth Quarter 2023 and Full Year 2023 Conference Call. This is your operator for today’s call. Please note that all lines have been placed on mute to prevent any background noise. This call is being recorded for replay purposes. A replay of the webcast will be available in the Investors section of the company’s website approximately two hours after the completion of the call and will be archived for at least 30 days. I will now turn the call over to your host for today, Mark Kinarney, Vice President of the Investor Relations. Mark?

Mark Kinarney: Thank you. Good morning and welcome to today’s call. With me are Mary Anne Heino, our CEO; Brian Markison, current Executive Chair of the Board and incoming CEO; Paul Blanchfield, our President; and Bob Marshall, our Chief Financial Officer. We’ll begin the call with Mary Anne’s introductory remarks followed by operational and strategic updates from Paul and Brian. Bob will cover our 2023 financial results and financial guidance for 2024. Mary Anne will provide closing remarks, and then we will open the call for Q&A. This morning, we issued a press release which was furnished to the Securities and Exchange Commission under Form 8-K reporting our fourth quarter and full year 2023 results. The release and today’s slide presentation are in the Investors section of our website at lantheus.com.

Any comments made during our call today could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties. Please note that we assume no obligation to update our commentary or any forward-looking statements except as required by applicable law even if actual results or future expectations change materially. Please refer to our SEC filings for a detailed discussion of these risks and uncertainties. Discussions during the call will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is also included on the Investors section of our website. It is my pleasure to now turn the call over to our CEO, Mary Anne.

Mary Anne Heino: Thank you, Mark and good morning everyone. Before we get started, I want to welcome Brian Markison as the company’s new Chief Executive Officer, effective March 1st. It was so important to the Lantheus Board and me that our new CEO will be able to drive forward the great work we have done. And in Brian, we have an experienced executive who intimately understands Lantheus, our strategy, and our industry. He brings decades of leadership experience in life science and deep expertise in oncology and neurology that will be essential to delivering on our strategic priorities. Welcome, Brian. 2023 was another stellar year at Lantheus, delivering record revenues, earnings and cash flows, bolstering our position as the leading radiopharmaceutical focused company.

I’m particularly proud that our products were used to impact the lives of more than 6 million patients and their families in 2023, a testament to our purpose to find it and follow disease to deliver better patient outcomes. For full year 2023, we reported revenue of approximately $1.3 billion, representing year-over-year growth of 39%, in line with what the company preannounced in early January. This growth was primarily driven by PYLARIFY and DEFINITY, both of which delivered strong performance of over 61% and 14% growth year-over-year, respectively, continuing solid momentum for 2024. PYLARIFY continues to grow with the potential to reach $1 billion in sales this year and remains the clear market leader offering a differentiated value proposition that, together with our operational excellence give us confidence that PYLARIFY will remain the number one PSMA PET imaging agent for prostate cancer patients, even amidst increasing competition and potential transitional pass-through expiry.

DEFINITY as well delivered solid growth and remains the ultrasound-enhancing agent of choice. Beyond our existing commercial diagnostics portfolio, we also made significant advancements across our radiopharmaceutical pipeline for both late and earlier-stage oncology therapeutics as well as oncologic and non-oncologic diagnostics. In mid-December, we reported positive top line Phase 3 SPLASH results for PNT2002. Our investigational PSMA-targeted radio therapeutics in development for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC. The SPLASH trial met its primary endpoint, demonstrating a statistically significant 29% reduction in the risk of radiographic progression or death. We continue to review the SPLASH study results and are specifically awaiting more mature overall survival data, which we currently accept later this year.

For PNT2003, our product candidate for the treatment of neuroendocrine tumors, we filed and the FDA accepted, our abbreviated new drug application, or ANDA. As expected, Novartis filed a patent infringement lawsuit, which triggered a potential 30-month stay under the Hatch-Waxman Act. We are very excited about the process of commercializing this important radio equivalent to LUTATHERA and look forward to a potential launch in 2025. As the leading radiopharmaceutical focused company, we continually explore opportunities to grow and expand our pipeline. We are particularly focused on identifying the targets and complementary isotopes that are best suited to treat certain diseases. As an example, we recently announced a strategic partnership with Perspective Therapeutics that provides us with options to add radioligand therapy or RLT assets to our pipeline and expand into alpha therapeutics.

If exercised, these options will allow us to diversify our RLT pipeline with Perspective Pb212 label product candidate and alpha-RLT for the treatment of neuroendocrine tumors currently in Phase 1/2a development. In addition, we have an opportunity to co-develop Perspective’s Pb212 isotope-based alpha-generating therapy candidates for prostate cancer. We are also investing in our innovative diagnostic pipeline. We continue to progress MK-6240, an F-18-based Tau [ph] PET tracer under development for the detection of tau tangles in patients with Alzheimer’s disease. To-date, it is being used in more than 90 clinical trials either as a staging tool or as a biomarker to identify patients to be enrolled in trials of Alzheimer’s disease therapeutic candidates.

We are finalizing the regulatory path to bring this exciting product candidate to market as a commercially approved agent. Similar to how PSMA PET imaging has transformed staging in patient selection for prostate cancer, we believe that Tau-based PET imaging agents like MK-6240 can play a similar role in staging and patient selection for Alzheimer’s disease treatment. With that, I’ll now turn the call over to Paul.

Paul Blanchfield: Thank you, Mary Anne and good morning. Our fourth quarter results demonstrated clear market leadership, operational excellence, and continued growth of the overall PSMA PET imaging market. We are pleased with PYLARIFY success and the impact that is made on the lives of those living with prostate cancer, including having been utilized for the diagnosis and staging of more than 300,000 patients since launch. PYLARIFY generated net sales of approximately $230 million in the fourth quarter and $851 million in 2023, up over 40% and 60%, respectively, from the prior year periods. Both quarterly and full year growth were driven by increasing utilization of PSMA PET with PYLARIFY at existing customers, complemented by our efforts to expand access through our distribution network to meet this growing demand.

We attribute our continued success to three primary factors: clinical differentiation, commercial differentiation, and operational excellence. Clinically, we believe PYLARIFY offers the best combination of our proprietary PSMA-targeted ligand and F-18 isotope. Our registrational trials demonstrated a high positive predictive value and high reader agreement, providing clinicians confidence in the accuracy and consistency of image interpretation and ultimately, in their patient management decisions. Commercially, PYLARIFY is the only PSMA imaging agent that is widely available through a diverse F-18 distributor supply network, ensuring convenient and reliable supply. In addition, more than 90% of covered lives have access to PSMA PET with PYLARIFY.

Operationally, we continue to grow PYLARIFY and maintain our market leadership in the PSMA diagnostic market through our educational and promotional efforts led by the industry’s largest customer-focused team. We also offer a best-in-class customer experience that enables healthcare providers and patients to access PYLARIFY with a 98% on-time in-full dose delivery rate. To ensure PYLARIFY remains the number one utilized PSMA PET imaging agent, we are actively working to mitigate the impact of PYLARIFY potential transitional pass-through expiration at the end of 2024. We have already taken steps to ensure we remain the market leader in 2025 and beyond and have and continue to build long-term strategic partnerships with select customers to ensure they have access to and preferably choose PYLARIFY as their PSMA PET agent of choice.

We are fiercely committed to ensuring PYLARIFY is available for patients, continues to grow, and remains the market leader. Finally, we continue to work with the centers for Medicare and Medicaid Services, or CMS, to create separate payment for radiopharmaceutical diagnostics, while also advocating for the FIND Act to ensure health equity for patients seeking access to innovative radiopharmaceutical diagnostics, including PYLARIFY. To support long-term growth, we are exploring the clinical utility of PYLARIFY in additional patient populations. We recently enrolled the first patient in the MIRROR study designed to determine whether PYLARIFY PSMA PET imaging can accurately detect the presence or absence of prostate cancer outside of the prostate gland in patients staged as favorable intermediate risk and importantly, how it can change intended management.

As we shared earlier this year, we see significant growth opportunity for PSMA PET imaging. We believe the current addressable market for PSMA PET is about 445,000 scans or $2 billion and could grow to a total addressable market of approximately 700,000 scans or more than $3 billion by 2029. To realize this, we anticipate the expansion of PSMA PET imaging into the favorable intermediate population supported by the MIRROR study and other real-world evidence. We anticipate PSMA therapeutics, both RLT and other modalities, will move into earlier lines of therapy, including both pre-chemo mCRPC and hormone-sensitive prostate cancer, which would increase the need for PSMA PET imaging. Finally, we expect the incidence and prevalence of prostate cancer to grow 2% to 3% per year.

As such, we believe there is a significant opportunity for PSMA PET to continue to grow and for PYLARIFY to maintain its market leadership. In our microbubble business, DEFINITY maintained its strong momentum with full year 2023 net sales of approximately $280 million, up 14% year-over-year. The drivers of success for this product continue to be its clinical and commercial value proposition supported by our operational excellence. Clinically, DEFINITY delivers high-resolution echocardiograms that improve cardiac diagnosis and patient management and has a proven safety profile across broad patient populations. Commercially, DEFINITY remains the clear market leader as the most utilized, extensively studied, and a trusted ultrasound-enhancing agent in the U.S. and is widely available with more than 95% of covered lives having access to DEFINITY.

Operationally, we have increased production of DEFINITY at our Lantheus manufacturing facility, which allows for enhanced supply chain redundancy, improved flexibility, and reduced cost. These improvements, along with our continued efforts to drive demand for DEFINITY, will ensure continued brand success. Switching now to our pipeline. In December 2023, we announced positive top line results from the Phase 3 SPLASH trial of PNT2002, in which the study met its primary endpoint. We continue to analyze the results and expect more mature overall survival data later this year prior to the potential submission of an NDA. We also plan to present the SPLASH results at a future medical conference. PNT2003 is an investigational RLP targeting somatostatin receptors with non-carrier-added lutetium with the potential to treat gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, as a radio equivalent to LUTATHERA.

Our ANDA filing with the FDA for PNT2003 underscores our commitment to making this therapy accessible furthering our purpose to improve patient outcomes through radio therapeutics and diagnostics. Based on public information, we believe Lantheus is the first applicant to have filed a substantially complete ANDA for Lutetium-177 dotatate. We estimate that PNT2003 has a current addressable U.S. market of approximately $1 billion that is expected to expand over $5 billion by 2029. In addition to our late-stage oncology pipeline, we have a number of earlier-stage assets, including the partnership with Perspective Therapeutics we recently announced. I’ll now hand it over to Brian, who will speak briefly about this latest opportunity.

A medical professional performing a pulmonary function assessment on a patient.

Brian Markison: Thank you, Paul and good morning everyone. As Mary Anne and Paul both mentioned, we are excited about the Perspective partnership, and I want to speak a bit more about why I think it’s a smart strategic opportunity for the company going forward. Our partnership with Perspective has three components. First, we have an option to license their promising Pb212 program in neuroendocrine tumors. Perspective is currently enrolling patients in a Phase 1/2a study progressing through the dose escalation phase, and we expect to have a look at initial data later this year. Second, we have an option to codevelop Perspective prostate cancer assets supported by their innovative Pb platform technology. And third, we took an equity position in the company because we believe that science behind the Pb alpha-based therapy platform, and we have secured the right of first offer and last look protections for any third-party merger and acquisition transactions involving Perspective for a 12-month period.

We recognize the transformative potential of Perspective Therapeutics alpha therapies and believe this partnership provides flexibility while preserving our capital for additional business development opportunities. We see Pb212 as one of the more promising isotopes for alpha therapy, especially when paired with Perspective proprietary chelator. We believe Perspective’s Pb212 key later may enable it to better retain the isotope at its daughters, including bismuth-212, thereby concentrating radiation at the target tumor and reducing off-hour target effects. This transaction aligns with our investment strategy to further expand our radiopharmaceutical pipeline with potential long-term benefits, allowing us to gain access to innovative therapies, technologies and establishing a collaborative partnership for sustained growth.

I will now turn the call over to Bob.

Bob Marshall: Thank you, Brian and good morning. I will provide highlights of the fourth quarter and full year 2023 financials, focusing on adjusted results unless otherwise noted. Revenue for the fourth quarter was $354 million, an increase of 34.5% over the prior year quarter. Revenue for the full year was $1.296 billion, an increase of 38.6% over 2022. And as was noted in the press release, we recognized a $15 million RELISTOR sales milestone achievement during Q4. Radiopharmaceutical oncology contributed $230.6 million of sales in the quarter, up 42.8% from the prior year quarter, attributable to the continued strength of PYLARIFY with sales of $229.9 million, up 43.1% year-over-year. Full year PYLARIFY sales totaled $851.3 million, an increase of 61.4%.

Precision Diagnostics revenue of $100.6 million was 6.6% higher over the prior year quarter. Sales of DEFINITY were $73.1 million, 14.9% higher as compared to the prior year. For the full year, DEFINITY contributed $279.8 million of sales, an increase of 14.2% over the prior year. TechneLite revenue was $21.5 million, down 13% versus the prior year comparable that included greater opportunistic sales. Full year TechneLite sales were $87.4 million, down 1.7%. Lastly, strategic partnership and other revenue was $22.8 million, up 214.9% over the prior year quarter, driven primarily by the aforementioned RELISTOR milestone contribution of $15 million and further bolstered by MK-6240’s performance of $6.4 million. For the full year, MK-6240 contributed $21.9 million.

RELISTOR contributed $29.3 million, which should be removed for comparison purposes of 2024 versus 2023 revenue. Gross profit margin for the fourth quarter was 69.3%, an increase of 251 basis points over the fourth quarter of 2022 on a similar basis. Full year gross profit margin was 68.7%, 221 basis points ahead of the prior year on favorable product mix offset by PMS investments and general inflationary pressures. Operating expenses at 22.4% of net revenue were 120 basis points higher than the prior year rate of 21.2% and within previously guided spending levels, particularly when adjusting revenue for the RELISTOR milestone. Increases in operating expenses reflect the investments made to support near- and longer-term growth initiatives across all functions of the organization, as was noted throughout last year.

Other income and expense was $0.9 million of income and as a result of net interest income offset by a reduction of a portion of our indemnified uncertain tax positions. Operating profit for the quarter was $165.7 million or an increase of 38.4% over the same period prior year. Total adjustments in the quarter were $28.3 million of expense before taxes. Of this amount, $14.2 million and $11.3 million of expense is associated with noncash stock and incentive plans and acquired intangible amortization, respectively. The remainder is related to acquisition, integration, and other non-recurring expenses. Our effective tax rate was 26.4% and 26.1% for the quarter and the full year, respectively. The resulting net reported net income for the fourth quarter was $103.4 million and $122.7 million on an adjusted basis, an increase of 27% over the prior year period.

GAAP fully diluted earnings per share for the fourth quarter were $1.47 and $1.75 on an adjusted basis, an increase from the prior year of 28%. On a full year basis, GAAP fully diluted earnings per share were $4.65 and $6.23 on an adjusted basis, an increase of 47.7% over the prior year. Now, turning to cash flow. Fourth quarter operating cash flow totaled $112.3 million as compared to $105.4 million in Q4 2022. Capital expenditures totaled $12.1 million, $7.3 million higher than the prior year quarter. Free cash flow, which we define as operating cash flow less capital expenditures, was $100.2 million, effectively flat with the prior year period and $258.7 million for the full year, which includes the $99.6 million CVR payment to former Progenics shareholders last May.

Taken together, cash and cash equivalents net of restricted cash, now stand at $713.7 million. We have access to our $350 million undrawn bank revolver and are very comfortable with our strong liquidity position. Turning now to our guidance for 2024 full year as well as the first quarter. We expect full year revenue growth to remain robust, led notably with PYLARIFY and DEFINITY. We will make strategic investments across the organization to support currently commercialized products drive stabilization efficiencies from our new ERP system, which went live at the beginning of this year, as well as advancing several important clinical pipeline efforts, which include PYLARIFY life cycle management and advancing MK-6240, among other projects. We forecast net PYLARIFY revenue to grow mid-teens due predominantly to volume growth, together with a slight annual net price benefit with sequential trends that should follow those noted throughout 2023.

PYLARIFY is supported by high single-digit growth from DEFINITY and relative steady contribution from the balance of the portfolio. Taken together, we estimate full year revenue to be in the range of $1.41 billion to $1.445 billion, an increase of approximately 11% to 14% over 2023 when excluding RELISTOR from the 2023 result. For modeling purposes, gross profit margin should be in line with 2023, even after considering the headwind created by the RELISTOR royalty divestiture mid last year. And as Paul mentioned, inclusive of our mitigation efforts to address the impacts of PYLARIFY’s potential traditional pass-through expiration at the end of 2024. Throughout 2024, we will continue to take steps to ensure we remain the market leader in 2025 and beyond by building long-term strategic partnerships with select customers.

Our operating expense forecast is expected to be in the range of 24% to 25% of revenue due to the investments noted earlier. Other interest income and expense should be reflective of our debt capital structure as well as approximately $36 million of interest income based on current and projected cash balances and forward interest rate curves. The effective tax rate assumed is 26.6%. Free cash flows are expected to be nearly double the 2023 results, providing significant strength to our balance sheet and ability to execute on our growth strategy and targeted acquisitions. Lastly, fully diluted shares to be between 71 million and 72 million shares. Therefore, for the full year, we expect fully diluted adjusted earnings per share to be in the range of $6.50 to $6.70.

For the first quarter, net revenue should be in the range of $347 million to $355 million. Fully diluted adjusted earnings per share should be in the range of $1.50 to $1.54. And again, for year-over-year comparison purposes, the prior year results had approximately $6 million of RELISTOR royalties or $0.06 of contribution in that quarter and should be removed. Lastly, for modeling purposes, depreciation and amortization for the full year 2024 should be approximately $12 million and $36 million, respectively, generally spread evenly throughout the year. Before turning the call back over to Mary Anne, I’d like to thank her for the last five-plus years of partnership and friendship. It has truly been an honored player that have worked alongside you.

And I dare say, on behalf of all employees, thank you, and we wish you the best.

Mary Anne Heino: Thank you, Bob, and I feel the same about our partnership. 2023 was another stellar year for Lantheus, delivering strong commercial and operational performance. As the leading radiopharmaceutical focused company, we will continue to leverage our deep expertise and our significant capital resources to advance and expand our pipeline. I would like to take a moment to express my gratitude for the incredible journey I have had at Lantheus. The organization has gone through significant change during my nine years as CEO, and we are now in an outstanding position to continue to lead the way in bringing novel radiopharmaceutical innovations to patients. This marks my last earnings call, and I’m thrilled to pass the tone to Brian.

I am confident Brian will lead Lantheus to new heights and are looking forward to remaining involved as the future of Lantheus unfolds. My role as Chair of the Board of Directors becomes official on March 1st, the same day that Brian assumes the role of CEO. To everyone across the Lantheus organization, I want to say thank you for all of your hard work and your dedication.

Brian Markison: Thanks, Mary Anne. I’m truly honored and excited to take on the role of CEO for Lantheus. Having served on the board, I’ve witnessed the unwavering dedication to our purpose, values and patients we serve. This transition is about continuity, building on the strong foundation established by Mary Anne, who has led us with great wisdom and vision. I look forward to leading this amazing team and continue our commitment to excellence, innovation and a shared purpose for the patient and for the benefit of our patients. With that, we’re now ready to take questions. Operator, please go ahead.

Operator: Thank you. [Operator Instructions] Our first question today will be coming from Anthony Petrone of Mizuho Group. Your line is open.

Anthony Petrone: Thank you. And I want to say congratulations again to Mary Anne. It was a great journey, enjoyed covering the company as from IPO through execution here. So, congratulations on a great run and go luck on the next chapter and also congratulations to Brian. I’ll start with PYLARIFY and just the guidance. The guidance for the full year in 1Q is actually ahead of our model. So, maybe just a little bit to scrub out the PYLARIFY drivers in there. A little bit of help on what we should be thinking about in terms of volume growth for PYLARIFY. That would be the first question. Are we baking anything for EU launch? And then lastly, price, is there any price baked in to the PYLARIFY equation for 2024? Thanks. And again, congratulations to everybody.

Mary Anne Heino: Thank you, Anthony.

Paul Blanchfield: Thanks Anthony. I really appreciate the question. So, as we mentioned in our formal guidance, we expect PYLARIFY to grow mid-teens this year, predominantly driven by volume with a slight annual net price benefit. I’ll speak to volume and price and then next on the EU piece. With PYLARIFY being the clear market leader, we do believe that it continues to offer value to the prostate cancer community and that our pricing is comparable to most other PSMA PET imaging agents on the market. We did take a 6% WACC price increase at the beginning of the year. I would note, we took price increase at the beginning of last year and the year before that as well. This is a large and growing market, and we believe there is ample room for multiple players and for sustained volume and revenue growth going forward. The overall guidance is predominantly focused on the U.S. and includes de minimis EU components at this point.

Bob Marshall: And Anthony, I’ll just tack on and just note that we’re sitting here at the end of February. And obviously, when you’re sitting here at this point in the quarter, it gives you some fairly decent insights into how the market is shaping up at this part of the year.

Anthony Petrone: No, that’s helpful. And then maybe one quick follow-up just on timing for rather expectations and the scenario analysis around reimbursement, there’s dual efforts out there for PYLARIFY. Maybe your latest thoughts on how CMS can settle out here as we approach the expiration of the transition pass-through status? And then any update on the FIND Act, and I’ll hop back in queue.

Paul Blanchfield: Thanks, Anthony. So transitional pass-through status, as we’ve noted before, impacts about 20% of prostate cancer patients and will impact the PSMA PET class as a whole with 3 of the 4 available agents losing transitional pass-through status in the first 9 months of 2025. To ensure, we remain the number one utilized PSMA PET imaging agent. We have, as I noted on my prepared remarks, continue to enter into long-term strategic partnerships with select customers to ensure they have access to and preferably choose PYLARIFY as their PSMA PET agent of choice. And we are fiercely, committed to ensuring PYLARIFY remains available for patients continues to grow and remains the clear market leader. We do continue to work with CMS and would expect proposed fiscal year 2025 rules to come out in July, but we do continue to have ongoing conversations with them to make them aware of the potential impact to patient access over time if the current TPT construct remains.

And then naturally, we continue to support legislation in both the House and the Senate, of which the FIND Act has been introduced and to ensure that Congress and the Senate understand the benefits for doing so. So that’s the nature of where we are. But naturally, we’re fiercely focused on defending, growing and continuing to ensure PYLARIFY remains the market leader going forward.

Operator: Thank you. Our next question was coming from Roanna Ruiz of Leerink Partners LLC.

Roanna Ruiz: Great. Good morning, everyone. So wanted to dig in a little bit more with PYLARIFY. Could you talk a bit about the evolving dynamic of PYLARIFY use between larger academic institutions and freestanding imaging centers? And how might that evolve in the next couple of years if you expect pass-through expiration for PYLARIFY?

Paul Blanchfield: It’s a great question, Ron. So overall, we view PSMA PET and indeed the bulk of pet imaging to be split roughly 60% hospital, 35% freestanding imaging center and approximately 5% government. Over time, the freestanding imaging centers continue to grow. They expand hospitals, in some cases, have been outsourcing them. And overall, we would expect that trend to continue as care moves outside the hospital system and into more of those freestanding centers. PET CT cameras are equally distributed relatively proportionately across those. And so naturally transitional pass-through status only impacts about 20% of patients or roughly one-third of the hospital business, recognizing that within the hospital, a portion of their business would be commercial payers, which is unimpacted by pass-through as well as Medicare Advantage, which is unimpacted.

And so you’re really looking at an overall minority of their business. And so we would expect those trends to continue to evolve with freestanding imaging centers continue to be more important. But I don’t think we expect dramatic shifts in the overall business going forward.

Operator: Thank you. Our next question will be coming from Richard Newitter of Truist Securities. Your line is open.

Richard Newitter: Hi. Thanks for taking the question. And congrats, Mary Anne on your next chapter and to Brian echoing Anthony’s comments. So I wanted to start off just on some of the mitigating strategies that you mentioned, Paul. If there’s any more for transitional pass due. Is there any more color you can provide on kind of what those are? And just in answering that question, you can address two things. One, I think I heard you say you expect PYLARIFY to continue growing. So is that a commitment to growth likely beyond transitional pass-through for PYLARIFY, and I would just imagine there’d be some pricing strategies in there as well as some impact to pricing. So if you could just comment on what, if anything, that would impact as you move through the year as some of those mitigating strategies get going in ’24? And then if you could elaborate on what those mitigating strategies actually mean?

Paul Blanchfield: So thanks for the question, Rich. As we noted in the prepared remarks, we do continue to enter into long-term strategic partnerships with select customers to ensure they have access to and preferably choose PYLARIFY. We are fiercely committed to ensuring PYLARIFY is available for patients continues to grow and remains the market leader. But given the competitive nature of the market, I don’t want to elaborate further on the specifics of those customer partnerships and what that means. That would be inappropriate at this point. But take it that we are fiercely focused on this. We talk about it on a daily basis, and we are focused on ensuring that PYLARIFY continues to grow, remains the market leader and is available for patients.

As we think towards long-term growth, as I mentioned, the overall PSMA PET market will continue to expand with the potential growing this year from approximately $2 billion to $3 billion plus by 2029. And so there is still ample opportunity to continue to grow. We have also noted that both on a quarterly and annual basis, the growth is not necessarily linear. As new indications become available and as the market expands, we are focused on the long term and continuing to grow.

Operator: Thank you. Our next question is coming from Yuan Zhi of B. Riley. Your line is open.

Yuan Zhi: Good morning. Glad to see the 2024 guidance. Can you guys talk about the current plan for PNT2002, any further clinical development in consideration? And is there any trigger point on those developments? Thank you.

Brian Markison: Yes. Thanks for the question. This is Brian. We’re closely watching 2002 in the SPALSH data, and we continue to look at various slices of the information that’s coming across, and we remain encouraged, quite frankly. Third quarter this year, we’re going to take a formal look prespecified at the data for 2002. And then we’ll see what that tells us, but we think we’re heading in the right direction.

Operator: Thank you. The next question is coming from Matt Taylor of Jefferies. Your line is open.

Matt Taylor: Hi. Thanks for taking the question. So I wanted to ask a follow-up question on PYLARIFY. I was just hoping that you could take us into the most updated competitive dynamics there? I guess what are you seeing from the traditional gallium competitors and any color that you can give us on how you see Blue are attacking in the market in the first part of this year.

Paul Blanchfield: Sure, Matt. So PYLARIFY, obviously, is the clear market leader in overall, having been used in more than 300,000 scans since launch. As the leader, we do disproportionately benefit from competition as more PSMA imaging agents come into the market, they raise awareness and naturally PYLARIFY benefits from that rising tide. Competitively, our estimates for market share have been relatively consistent over the past 2 quarters, with PYLARIFY share in the mid- to high 60% range. I would note that’s an estimate as only two of the four, now five players report product-specific revenue. Importantly, I would note that our market revenue leadership continues to expand and indeed solidify both annually where we grew from the fourth quarter of 23% versus the fourth quarter of ’22, $86 million year-over-year as well as sequentially, where we expand from 3Q to 4Q by $14 million, with that revenue dollar growth outpacing that of our competition.

And therefore, the impact that we’ve seen both in the fourth quarter and is factored into our guidance is minimal impact from recently approved F-18 agents. Overall, we believe there’s a lot of growth left in the PSMA pet market, as evidenced by the CAM of $2 billion, growing to potentially a $3 billion TAM. And we’re focused, as I’ve mentioned, on ensuring PYLARIFY, remains accessible to patients, continues to grow and remains the clear market leader.

Operator: Thank you. Next question will be coming from Justin Walsh of Jones Trading. Your line is open.

Justin Walsh: Hi. Thanks for taking the question. I think there’s a lot of excitement and interest around PD-L1 SAP and tow from a clinical perspective. I was wondering if you could comment on thoughts about the relative commercial potential of the various imaging biomarkers.

Mary Anne Heino: So I’ll take that, and I’ll focus on MK6240 and what we see there. As you heard in my remarks, we’re really excited about the task we see forward for potential commercial application with that product. Currently, it’s being used in clinical trials, which with radiotracers you were approved and allowed to do that. And as I said, it’s available and being used in over 90 clinical trials. But when you start looking at the commercial opportunity, and I’m here, I’ll kind of bifurcate my remarks between commercial opportunity from a revenue perspective but then really from a value perspective. And I purposely said in my remarks that we see a corollary between what PSMA imaging was able to bring from a relative value perspective to prostate cancer diagnosis and treatment selection.

We see that same potential in Alzheimer’s disease, which would represent really a big step forward for the physicians who are trying to accurately diagnose and then select treatment options for those patients. And so that’s what really excites us about, now we have not yet announced our commercial regulatory strategy, but it is something that we are actively looking at and also engage, of course, with the FDA on. And so you’ll hear us, well, not me, but you’ll hear this team talking more and more about that into the future.

Paul Blanchfield: And maybe I’ll just expand Mary Anne. Just on the specific market opportunities. We did share earlier this year that we view the addressable market for MK6240, specifically as Alzheimer’s treatments come to market and the ability to be used for both patient staging and selection of approximately $1.5 billion by the end of the decade. And so clearly, another large opportunity with MK6240 being used in over 90 clinical trials certainly has an opportunity to be to partner with those therapeutics come to market. For the FAP agent, we are equally excited. Naturally, it’s a little bit earlier in development. We have not put a market potential on that yet. But I would note that we think about pan-cancer PET imaging agents, FDG, which has been around for over 30 years, does north of 2 million scans per year. So if you think about the market potential, it’s a large opportunity.

Operator: Thank you. Our next question is coming from Andy Hsieh of William Blair. Your line is open.

Andy Hsieh: Thanks for taking my question. I wanted to dig in more on the Prospective deal. Curious if you can talk about the strategic positioning. You envisioned for various assets that you mentioned on the call. Specifically, maybe where do you think you will be positioned? Would it be slotted in the post-lutetium setting or before given that there’s a pretty material difference in path length. And also the supply chain, will Perspective be providing the generators on site on the clinical trial site? And what’s the kind of long-term capacity that we should be thinking about? Thank you so much.

Mary Anne Heino: So I’ll take that question for the group, and then anyone else can add in. I think, first, to your question about where across the kind of the spectrum of prostate cancer can these assets be applied. You’re exactly right to ask kind of be pre or post chemo, which would then kind of describe in relation to where the lutetium-based products are being used. And the answer is yes and yes. That is something I think we’re all learning as we look at SPALSH, as we look at PSM4, as we look at the original VISION trial, it really does help us, I would say, evaluate where these products are best placed. And as I believe Paul might have had in his comments, we see these products moving earlier in line of therapy because of the benefit that they can receive especially with respect to the side effect profile, the total kind of, I would say, safety versus benefit profile of these products versus chemo agents.

So that is something that, again, we have not yet been public about. It’s something we’re working with perspective on to decide what the best application for these products are as we bring them in their first applications to market. With respect to the supply chain, it’s a really good question. And the lead 212 based isotopes right now have more than one option, I’ll say, as to how to come to the channel. You can either because of the half-life, you have the option here to either do kind of central manufacturing distribution or regional distribution or a combination of both, depending on what market you’re in. And there, again, we have not been specific yet. And I would actually reference you to perspective to their website, they’ve got some information and some material on their website that speaks to the efforts they’ve already undertaken for supply chain.

It is, as you — I think you were noting, it is something that needs to reach commercial scale before we get to market. But we’re confident that, that can be achieved.

Brian Markison: Yes. I think I’ll just add to that a little bit. Their lead program in neuroendocrine tumors has us very interested. And we think it has the potential to be best-in-class, and that’s one that we’re very close to as well. So we like their platform. We like the targets they have and we especially like their Lead program.

Operator: Thank you. Our next question comes from Larry Solow of CJS Securities. Your line is open.

Larry Solow : Great. Thank you and Mary Anne, congratulations to you as well. It’s been a good six-year run for CJ myself, so.

Mary Anne Heino : I know. Thanks, Larry.

Larry Solow : Absolutely. Brian, welcome. We look forward to working with you. Just a question for both of my questions been answered. But a question for you. It looks like if I do the math on the guidance sort of at the midpoint of your revenue guidance kind of slow that down to the midpoint of EPS guidance. It looks like margins up modestly with 50 to 100 bps on the operating line, about right? And where is that going to shake out? Is it a little bit more on the gross margin side? Or do you get a little leverage? And then part two of that question is, are you building in some increased expenses or material increases for PNT2002 this year? Or is that more of a weighting it? Thanks.

Bob Marshall : All right. Thanks, Larry. That’s a great set of questions. Margins should be relatively flat, maybe slightly improved. But again, I think if you peel out the impact of the RELISTOR royalty out of the prior year, that’s about an 80 basis point headwind. So to remain flat is actually an increase. And you’re right, that is coming from product mix in terms of PYLARIFY and DEFINITY as well as some of the other cost containment factors being able to manufacture DEFINITY on campus that’s contributing and helping. And yes, you are seeing an increase in overall spend, but I can tell you that we don’t have spend for 2002 embedded in our expenses. And mainly, that’s because we want to make sure that we’re phase-gating. So as Brian indicated earlier in Paul’s remarks, we’re waiting for the data to mature before we put further investment.

And when that data does read out, we will make or not make investment as appropriate, and we’ll communicate that to the Street. I think another driver is the byproduct of having a lot of cash on the balance sheet and there is significant. And when I look through the consensus models, I did note that it’s sort of underappreciated the current level of interest rates and the forward curves that we see. So with this level of cash, it does generate that level of interest income that I noted in my scripted remarks around $36 million. Tax team does a good time — it does a good job. So as you kind of work down through the P&L, that’s what’s creating our opportunity to continue to expand and drive profitability for the company, while taking the opportunity to invest appropriately across many aspects of the organization, whether that be all the things that Paul talked about in terms of PYLARIFY protection and mitigation strategies as well as market access, market research, business development activities, which can be consuming and expensive.

But also the things that we’ve done with our ERP. The company did a fantastic job putting that in place. But it does come with a cost. But at the same time, those costs will ultimately drive workflow efficiencies that I think will continue to provide opportunities to invest in other aspects of our business, much like our R&D pipeline.

Operator: Thank you. Our next question is coming from Kemp Dolliver of Brookline Capital Markets. Your line is open.

Kemp Dolliver: Thank you and good morning. My question relates to PNT2003 and the market potential data. Could you just speak quickly about what drives the increases in the TAM between 2024 and 2029 because point you had indicated both a traditional generic strategy and then ultimately, an NDA strategy for different indications in the GetNet space. So if you — or the net space. Could you just speak to that in a little more detail?

Paul Blanchfield: Yes, I’m happy to take that. So as we noted in our prepared remarks, we did submit an ANDA for PNT2003, which has been accepted by the FDA. And based on available public information, we believe we are the first applicant. The market we estimate currently has an addressable market of about $1 billion in 2024, and that’s actually on one of the prepared slides. And that’s about 4,000-plus patients with a real focus on metastatic second-line within GetNet. As we’ve seen from recent trial results in potential expanded use of the somatostatin receptor targeted RLT, we believe there’s an opportunity for the overall market to grow specifically in first line as well as into other nets as well as Phelan Para. And so when we look at what that potential is from a utilization.

It won’t necessarily change the proposed labels. This is more likely updates to guidelines, which would expand the potential use of this asset class into those, and that’s really driving much of the expansion. And then as you get out in five years, there’s really just continued expansion of overall incidence and prevalence. And fortunately, more men and women continue to be diagnosed and present with these. And so overall, we view this as a large market opportunity with multiple room for additional players in luting PNT2003, and we’ll certainly be talking more about this opportunity and our go-to-market strategy as we get closer to 2026 and a potential launch.

Operator: Thank you. Our next question will be coming from David Turkaly of JMP Securities. Your line is open.

David Turkaly : Good morning. You mentioned the ferocity of some of your long-term partnerships. So I guess I just wanted to ask can you sign these things, can they be exclusive? And can they be multiyear, like can you have contracts that go through 2025 and 2026. I’m just trying to get a sense of that word and then sort of what you can do with these customers to potentially maybe lack some of them up.

Mary Anne Heino : I’m just going to start by clarifying. We said we were fiercely willing to fiercely defend our business, but we would not describe our partnerships as ferocious. They’re very amiable and they’re two-way, but I’ll let Paul speak more to what our strategy is there.

Paul Blanchfield: No. I appreciate the question. Naturally, I’m not going to go into significant detail given the competitive nature of it. But yes, we can’t enter into long-term contracts by that, I mean, multiyear with key customers to ensure that PYLARIFY remains their preferred choice of agent I’ll wait until over time to discuss more about what those specifically mean. But we have an incredibly experienced commercial team, I think, which includes market access, national accounts and overall sales team that is very well experienced in working with commercial customers that we know deeply and have built long-term relationships over the last number of years. And these strategic partnerships help codify that relationship and ensure that we remain solid partners together for years to come.

Mary Anne Heino : I’ll just add also you made a reference to whether these partnerships were exclusive, and it is very atypical in the radiopharmaceutical space to ask for exclusivity just because of the supply chain and supply chain considerations for these products, our strategy would be to retain PYLARIFY’s role as the most chosen and market-leading choice for PSMA-based imaging.

Operator: Thank you. Our final question of the day will be from Richard Newitter of Truist Securities. Your line is open.

Richard Newitter : Hi. Thanks for taking the follow-up. I just had one additional one. On transitional past due, one of your competitors has talked publicly about product life cycle management, possibly even restarting the transitional pass-due clock for a next-generation type diagnostic offering if it can get approved through the FDA. I’m just curious if you have any views on this kind of strategy? Is there anything you have in the pipeline beyond indication expansion, I appreciate the MIRA study and intermediate favorable indication expansion, and that sounds promising, but more specific to the product life cycle management concept? Thank you.

Paul Blanchfield: Yes. No. I understand the question, Rich, appreciate it. We’re not going to comment publicly on what our competitors and of other public companies have said. As you noted, we are focused on life cycle management with PYLARIFY, both the MIRROR study as well as assessing its use in non-prostate cancer because PSMA is expressed by other solid tumors. For pass-through, our primary focus is really to work with customers to ensure that we remain the preferred agent of choice and then naturally to engage with CMS to support legislation as well as should CMS to support regulation and then work with the FIND Act specifically supporting legislation. And so I’m not going to comment publicly on what competitors have stated about their life cycle management.

We believe PYLARIFY is the clear market leader. We believe the market is large and continues to grow, and we are focused on ensuring it remains accessible to patients that PYLARIFY continues to grow and then it remains the clear market.

Operator: Thank you. Ladies and gentlemen, there are no further questions at this time. Thank you for participating in today’s conference. This concludes the program. You may disconnect, and have a wonderful day.

AI Assistant

LANTHEUS HOLDINGS INC

Q4 2023

Earnings Transcript

Find Answers

Ask about any part of the document to get insights, explanations, or key details.